Aradigm increases SmartMist production:
This article was originally published in Clinica
Executive Summary
Aradigm is scaling-up production of its SmartMist drug delivery system for a 1997 launch following 510(k) clearance by the US FDA. Phase I clinical trials for the inhalation delivery of morphine using the company's AERx system are under way and the company is conducting clinical feasibility studies for insulin delivery and diagnostic pulmonary imaging. The Californian company raised $24.7 million in its IPO in June (see Clinica No 713, p 15). Aradigm's six-month net losses were $3.7 million against revenues of $172,500.
You may also be interested in...
Sandoz Pioneers Posaconazole And Silodosin In Canada
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
Amarin Pulls Insurer Into Hikma/Vascepa Induced Infringement Suit
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
Dutch Supplements Firm Caught Buying Fake Instagram Followers
Netherlands' Authority for Consumers and Markets has reprimanded a dietary supplements player for purchasing fake followers and likes on social media to exaggerate the popularity of its products. It is the first case of its kind in the country.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: